- Home
- PACB
as 03-06-2025 2:41pm EST
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 364.2M | IPO Year: | 2010 |
| Target Price: | $2.79 | AVG Volume (30 days): | 14.5M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $5.01 | Next Earning Date: | 02-13-2025 |
| Revenue: | $154,014,000 | Revenue Growth: | -23.19% |
| Revenue Growth (this year): | 9.91% | Revenue Growth (next year): | 28.57% |
Stock Insider Trading Activity of Pacific Biosciences of California Inc. (PACB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farmer Michele | PACB | See Remarks | Mar 3 '25 | Sell | $1.41 | 2,973 | $4,183.01 | 184,619 | |
| Van Oene Mark | PACB | See Remarks | Mar 3 '25 | Sell | $1.41 | 6,486 | $9,125.80 | 1,497,695 | |
| HENRY CHRISTIAN O | PACB | See Remarks | Mar 3 '25 | Sell | $1.41 | 12,497 | $17,583.28 | 2,225,357 | |
| Van Oene Mark | PACB | See Remarks | Feb 18 '25 | Sell | $1.88 | 100,773 | $189,251.69 | 1,497,695 | |
| HENRY CHRISTIAN O | PACB | See Remarks | Feb 18 '25 | Sell | $1.88 | 259,909 | $488,109.10 | 2,225,357 | |
| Van Oene Mark | PACB | See Remarks | Jan 10 '25 | Sell | $2.03 | 34,405 | $69,979.77 | 1,497,695 |
Latest Pacific Biosciences of California Inc. News
PACB Breaking Stock News: Dive into PACB Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%
GlobeNewswire
15 days ago
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
TipRanks
19 days ago
PacBio should return to growth over time, says Canaccord
Simply Wall St.
20 days ago
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations
GlobeNewswire
20 days ago
PacBio Grants Equity Incentive Award to New Employee
Zacks
20 days ago
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
MT Newswires
21 days ago
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating
GuruFocus.com
21 days ago
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ...
Compare PACB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PACB Pacific Biosciences of California Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.